SlideShare a Scribd company logo
1 of 38
RHEUMATOID
ARTHRITIS
DEFINITION
 Rheumatoid arthritis (RA) is a chronic and usually
progressive inflammatory disorder of unknown
etiology characterized by polyarticular symmetrical
joint involvement and systemic manifestations.
 Rheumatoid arthritis (RA) is a chronic, systemic
autoimmune disease that involves inflammation in
the membrane lining of the joints and often affects
internal organs.
 Most patients exhibit a chronic fluctuating course
of disease that can result in progressive joint
destruction, deformity, and disability.
 It occurs three times more often in women, and
peaks at age 35 to 50 years.
Rheumatoid arthritis is a chronic
disease, characterized by periods of
disease flares and remissions.
The cause of rheumatoid arthritis
is not known.
In rheumatoid arthritis, multiple
joints are usually, but not always,
affected in a symmetrical pattern.
Rheumatoid arthritis can affect
people of all ages.
Damage to joints can occur early
and does not correlate with the
severity of symptoms.
The "rheumatoid factor" is an
antibody that can be found in the
blood of 80% of people with
rheumatoid arthritis.
 The cause of RA is not fully understood but
appears to be multifactorial.
 It is considered an autoimmune disease in which
the body loses its ability to distinguish between
synovial and foreign tissue. Other factors
involved in RA are as follows:
 1. Environmental influences, such as infections
or trauma, smoking and tobacco are thought to
trigger the development of RA.
ETIOLOGY
2.Genetic markers, such as human leukocyte antigen
DR4 (HLA-DR4), have been associated with
triggering the inflammatory process in RA. Such
markers, however, are not considered diagnostic
because 30% of people with HLA-DR4 never develop
RA.
3.Antigen-dependent activation of T lymphocytes
leads to proliferation of the synovial lining,
activation of proinflammatory cells from the bone
marrow, cytokine and protease secretion, and
autoantibody production.
4.Anticitrullinated proteins and peptides are high
specific for RA.
5.Tumor necrosis factor & (TNF-&), IL-1, IL-6,
IL-8, and growth factors propagate the
inflammatory process, and agents found to alter
these cytokines show promise in reducing pain and
deformity.
6.Inflamed synovium is a hallmark of the
pathophysiology of RA. Synovium proliferates
abnormally, growing into the joint space and into the
bone, forming a pannus. The pannus migrates to
the articular cartilage and into the subchondral bone
leading to destruction of cartilage, bone,
tendons, and blood vessels.
Genetic and environmental factors play a part.
Gender. Women before the menopause are affected
three times more often than men. After the menopause
the frequency of onset is similar between the sexes,
suggesting an etiological role for sex hormones. The use
of the oral contraceptive pill has shown no affect on RA
overall, as previously thought, but it may delay the
onset of disease.
Familial. The disease is familial with an increased
incidence in first degree relatives and a high
concordance amongst monozygotic twins (up to 15%)
and dizygotic twins (3.5%). In occasional families it
affects several generations.
12
Genetic factors are estimated to account for up to 60%
of disease susceptibility.
There is a strong association between susceptibility to RA
and certain HLA haplotypes. HLA-DR4, which occurs in
50–75% of patients, correlates with a poor prognosis, as
does HLA-DRB1. Individuals with HLA-DRB1 combined
with a positive rheumatoid factor are13 times greater
risk for developing bone erosions in early disease.
13
Hands and wrists
Shoulders
Elbows
Feet
Knees
Hips
Cervical spine
 Chronic inflammation of the synovial tissue
lining the joint capsule results in the proliferation
of this tissue. The inflamed, proliferating
synovium characteristic of rheumatoid arthritis is
called pannus. This pannus invades the cartilage
and eventually the bone surface, producing
erosions of bone and cartilage and leading
to destruction of the joint. The factors that initiate
the inflammatory process are unknown.
The immune system is a complex network of checks
and balances designed to discriminate self from non-
self (foreign) tissues. It helps rid the body of
infectious agents, tumour cells, and products
associated with the breakdown of cells. In
rheumatoid arthritis, this system no longer can
differentiate self from non-self tissues and
attacks the synovial tissue and other connective
tissues.
Signs & Symptoms of RA
• Fatigue.
• Stiffness, especially in early morning and
after sitting a long period of time.
• Not relieved by pain
• Low Grade Fever, Weakness.
• Muscle pain and pain with prolonged sitting.
• Symmetrical, affects joints on both sides of
the body.
• Rheumatoid nodules.
• Deformity of your joints over time.
• Raynauds phenomenon.
• Pain
 1. Rheumatoid factor (RF) is found in
" 60% of patients with RA; however, as
many as 5% of healthy individuals will
have elevated titers of RF. If initially
negative, the test can be repeated in 6
to 12 months. RF is not an accurate
measure of disease progression.
LABORATORY ASSESSMENT
2.Erythrocyte sedimentation rate (ESR) and C-
reactive protein (CRP) :
They are markers of inflammation and are usually
elevated in patients with RA. They can also help
indicate the activity of the disease, but they do not
indicate disease severity.
3.Anticyclic citrullinated peptide antibodies
(ACPA) :
These are found in most patients with RA and are
useful in predicting erosive disease.
Radiographic examination:
This can reveal the extent of bone
erosion and cartilage loss. An MRI can
detect proliferative pannus.
Rheumatoid Arthritis
 Symptom criteria
– Morning stiffness
– Arthritis of 3 or more joints
– Arthritis of hand joints
– Symmetric arthritis
– Rheumatoid nodules
– Serum rheumatoid factor
– Radiographic changes
 A person shall be said to
have rheumatoid arthritis
if he or she has satisfied
4 of 7 criteria, with
criteria 1-4 present for at
least 6 weeks
Diagnosis and clinical evaluation:
In 2010, EULAR (European League Against
Rheumatism) established a score-based algorithm
criteria aimed at diagnoses before joint damage
occurs. Definitive RA is defined as a score # 6/10
based on four domains:
1.Joint involvement (e.g., number and location of
involved joints)
2. Serology (e.g., RF, ACPA)
3. Acute phase reactants (e.g., CRP, ESR)
4. Duration of symptoms
Treatment objectives
 The goals in the management of RA are:
 1. To prevent or control joint damage
 2. To prevent loss of function
 3. To decrease pain
 4. To maintain the patient’s quality of life
 5. To avoid or minimize adverse effects of
treatment.
 6. Preservation of muscle and joint function.
 7. Return to a desirable and productive life.
ALGORITHM OF TREATMENT OF RA
Methotrexate Or other DMARD ± NSAID
± Prednisone within first 3 months
Poor response
Other DMARD mono Rx
(MTX if not used above)
Combo DMARD Rx Biologic DMARD
Mono or combo with DMARD
Poor response
Try other combination, triple drug (DMARD + Biologic), add low dose of
Prednisone for long term, consider second line DMARD.
Non pharmacological Treatment
 Diet
 Exercise
 Acupuncture
 Herbal Medicines
 Massage
 Stress Reduction Techniques –
prayer, meditation, hypnosis, yoga.
Nutrition
The most commonly observed vitamin and
mineral deficiencies in patients with RA
are:
o folic acid
o vitamin C
o vitamin D
o vitamin B6
o vitamin B12
o vitamin E
o calcium
o magnesium
o zinc
o selenium
Exercise
4 times a week for
30 minutes
Being overweight strains joints and leads to further
inflammation.
•Walking
•Light jogging
•Water aerobics
•Cycling
•Yoga
•Tai chi
•stretching
Medications
 There are four types of medications used
to treat RA:
– Non-steroidal anti-inflammatory drugs
(NSAIDs)
– Disease-modifying anti-rheumatic
drugs(DMARDS).
– Corticosteroids
– Biologic Response Modifiers
(“Bioligics”)
(Arthritis Foundation, 2012; Gulanick & Myers 2011)
Non-steroidal anti-inflammatory drugs (NSAIDs)
Examples General Use Side Effects Nursing
Considerations
Aspirin, ibuprofen,
naproxen, COX-2
inhibitors, propionic
acid, phenylacetic
acid
•anti-
inflammatory:
Used in the
management
inflammatory
conditions
•Antipyretic:
used to control
fever
•Analgesic:
Control mild to
moderate pain
•Nausea
•Vomiting
•Diarrhea
•Constipation
•Dizziness
•Drowsiness
•Edema
•Kidney failure
•Liver failure
•Prolonged
bleeding
•Ulcers
•Use cautiously in
patients with Rx
of bleeding
disorders
•Encourage pt to
avoid concurrent
use of alcohol
•NSAIDs may
decrease
response to
diuretics or
antihypertensive
therapy
Corticosteroids
Examples General Use Side Effects Nursing
Considerations
Cortisone,
hydrocortisone,
prednisone,
betamethasone,dex
a-methasone
•Used in the
management
inflammatory
conditions
•When
NSAIDS may
be
contraindicate
d
•Promptly
improve
symptoms of
RA
•Increased
appetite
•Weight gain
•Water/salt
retention
•Increased blood
pressure
•Thinning of skin
•Depression
•Mood swings
•Muscle
weakness
•Osteoporosis
•Delayed wound
healing
•Onset/worsenin
g of diabetes
•Take
medications as
directed (adrenal
suppression)
•Used with
caution in
diabetic patients
•Encourage diet
high in protein,
calcium,
potassium and
low in sodium
and
carbohydrates
•Discuss body
image
•Discuss risk for
infection
Disease-modifying anti-rheumatic drugs(DMARDS)
Examples General Use Side Effects Nursing
Considerations
Methotrexate
(the gold
standard)
, gold salts,
cyclosporine,
sulfasalazine,
azathioprine
•immunosuppressiv
e activity
•Reduce
inflammation of
rheumatoid arthritis
•Slows down joint
destruction
•Preserves joint
function
•Dizziness,
drowsiness,
headache
•Pulmonary
fibrosis
•Pneumonitis
•Anorexia
•Nausea
•Hepatotoxicity
•Stomatitis
•Infertility
•Alopecia
•Skin ulceration
•Aplastic anemia
•Thrombocytopeni
a
•Leukopenia
•Nephropathy
•fever
•photosensitivity
•May take several
weeks to months
before they
become effective
•Discuss
teratogenicity,
should be taken
off drug several
months prior to
conception
•Discuss body
image
Biologic Response Modifiers (“Biologics”)
Examples General Use Side Effects Nursing
Considerations
Etanercept, anakinra,
abatacipt,
adalimumab,
Infliximab
(Remicade)
•Used in the
management
inflammatory
conditions
•When
NSAIDS may
be
contraindicate
d
•Promptly
improve
symptoms of
RA
•Increased
appetite
•Weight gain
•Water/salt
retention
•Increased blood
pressure
•Thinning of skin
•Depression
•Mood swings
•Muscle
weakness
•Osteoporosis
•Delayed wound
healing
•Onset/worsening
of diabetes
•T
ake medications
as directed
(adrenal
suppression)
•Encourage diet
high in protein,
calcium,
potassium and
low in sodium and
carbohydrates
•Discuss body
image
•Discuss risk for
infection
Questions? 
?
• V
COMMENT ON THERAPY

More Related Content

Similar to rheumatoidarthritispptbyann-160402080357.pptx

Rheumatoid arthritis
Rheumatoid arthritisRheumatoid arthritis
Rheumatoid arthritissgpharshida
 
Allison D.docx
Allison D.docxAllison D.docx
Allison D.docxwrite22
 
Rheumatoid arthritis.pptx
Rheumatoid arthritis.pptxRheumatoid arthritis.pptx
Rheumatoid arthritis.pptxHudaSaber1
 
Rheumatoid arthritis
Rheumatoid arthritisRheumatoid arthritis
Rheumatoid arthritisSijo A
 
RA Rheumatoid Arthritis
RA Rheumatoid ArthritisRA Rheumatoid Arthritis
RA Rheumatoid ArthritisHuzaifaMD
 
Rheumatoid-Arthritis-Causes-Symptoms-and-Treatments
Rheumatoid-Arthritis-Causes-Symptoms-and-TreatmentsRheumatoid-Arthritis-Causes-Symptoms-and-Treatments
Rheumatoid-Arthritis-Causes-Symptoms-and-TreatmentsAnn-Marie Colacino
 
Rhematoid arthritis by dr shyam sunder sharma
Rhematoid arthritis by dr shyam sunder sharmaRhematoid arthritis by dr shyam sunder sharma
Rhematoid arthritis by dr shyam sunder sharmadrshyamsundersharma
 
SEMINAR PRESENTATION ON RHEUMATOID ARTHRITIS.pptx
SEMINAR PRESENTATION ON RHEUMATOID ARTHRITIS.pptxSEMINAR PRESENTATION ON RHEUMATOID ARTHRITIS.pptx
SEMINAR PRESENTATION ON RHEUMATOID ARTHRITIS.pptxmrcopyxerox
 
Rheumatoid arthritis 2019
Rheumatoid arthritis 2019Rheumatoid arthritis 2019
Rheumatoid arthritis 2019AdesewaPearl
 
Rheumatoid Arthritis
Rheumatoid Arthritis Rheumatoid Arthritis
Rheumatoid Arthritis rishilaxmi
 
Rheumatoid arthritis and osteoarthritis presentation by Madhukar S Thagnar ....
Rheumatoid arthritis  and osteoarthritis presentation by Madhukar S Thagnar ....Rheumatoid arthritis  and osteoarthritis presentation by Madhukar S Thagnar ....
Rheumatoid arthritis and osteoarthritis presentation by Madhukar S Thagnar ....MadhukarSureshThagna
 
Rheumatoid arthritis
Rheumatoid arthritisRheumatoid arthritis
Rheumatoid arthritissmisree
 
Conceptual Study of Amavat (Disease review) by Vd. Ram Shukla
Conceptual Study of Amavat (Disease review) by  Vd. Ram ShuklaConceptual Study of Amavat (Disease review) by  Vd. Ram Shukla
Conceptual Study of Amavat (Disease review) by Vd. Ram ShuklaProf. Surendra Soni
 

Similar to rheumatoidarthritispptbyann-160402080357.pptx (19)

Rheumatoid arthritis
Rheumatoid arthritisRheumatoid arthritis
Rheumatoid arthritis
 
Allison D.docx
Allison D.docxAllison D.docx
Allison D.docx
 
Rheumatoid copy
Rheumatoid   copyRheumatoid   copy
Rheumatoid copy
 
Rheumatoid arthritis.pptx
Rheumatoid arthritis.pptxRheumatoid arthritis.pptx
Rheumatoid arthritis.pptx
 
Rhematoid arthritis
Rhematoid arthritisRhematoid arthritis
Rhematoid arthritis
 
Rheumatoid arthritis
Rheumatoid arthritisRheumatoid arthritis
Rheumatoid arthritis
 
Musculoskeletal disorders
Musculoskeletal disordersMusculoskeletal disorders
Musculoskeletal disorders
 
RA Rheumatoid Arthritis
RA Rheumatoid ArthritisRA Rheumatoid Arthritis
RA Rheumatoid Arthritis
 
Rheumatoid-Arthritis-Causes-Symptoms-and-Treatments
Rheumatoid-Arthritis-Causes-Symptoms-and-TreatmentsRheumatoid-Arthritis-Causes-Symptoms-and-Treatments
Rheumatoid-Arthritis-Causes-Symptoms-and-Treatments
 
Rhematoid arthritis by dr shyam sunder sharma
Rhematoid arthritis by dr shyam sunder sharmaRhematoid arthritis by dr shyam sunder sharma
Rhematoid arthritis by dr shyam sunder sharma
 
Harman toor
Harman toorHarman toor
Harman toor
 
SEMINAR PRESENTATION ON RHEUMATOID ARTHRITIS.pptx
SEMINAR PRESENTATION ON RHEUMATOID ARTHRITIS.pptxSEMINAR PRESENTATION ON RHEUMATOID ARTHRITIS.pptx
SEMINAR PRESENTATION ON RHEUMATOID ARTHRITIS.pptx
 
Rheumatoid arthritis 2019
Rheumatoid arthritis 2019Rheumatoid arthritis 2019
Rheumatoid arthritis 2019
 
Rheumatoid Arthritis
Rheumatoid Arthritis Rheumatoid Arthritis
Rheumatoid Arthritis
 
REMATHOID ARTRITIS
REMATHOID ARTRITISREMATHOID ARTRITIS
REMATHOID ARTRITIS
 
Rheumatoid arthritis and osteoarthritis presentation by Madhukar S Thagnar ....
Rheumatoid arthritis  and osteoarthritis presentation by Madhukar S Thagnar ....Rheumatoid arthritis  and osteoarthritis presentation by Madhukar S Thagnar ....
Rheumatoid arthritis and osteoarthritis presentation by Madhukar S Thagnar ....
 
Rheumatoid arthritis
Rheumatoid arthritisRheumatoid arthritis
Rheumatoid arthritis
 
Conceptual Study of Amavat (Disease review) by Vd. Ram Shukla
Conceptual Study of Amavat (Disease review) by  Vd. Ram ShuklaConceptual Study of Amavat (Disease review) by  Vd. Ram Shukla
Conceptual Study of Amavat (Disease review) by Vd. Ram Shukla
 
rheumatoid arthritis
rheumatoid arthritisrheumatoid arthritis
rheumatoid arthritis
 

More from Imtiyaz60

asthma .pptx
asthma                                             .pptxasthma                                             .pptx
asthma .pptxImtiyaz60
 
Asthma and COPD PATHOPHYSIOLOGY .pptx
Asthma and COPD PATHOPHYSIOLOGY    .pptxAsthma and COPD PATHOPHYSIOLOGY    .pptx
Asthma and COPD PATHOPHYSIOLOGY .pptxImtiyaz60
 
Angina and MI PATHOPHYSIOLOGY .pdf
Angina and MI PATHOPHYSIOLOGY       .pdfAngina and MI PATHOPHYSIOLOGY       .pdf
Angina and MI PATHOPHYSIOLOGY .pdfImtiyaz60
 
ATHEROSCLEROSIS pathophysiology .pptx
ATHEROSCLEROSIS pathophysiology    .pptxATHEROSCLEROSIS pathophysiology    .pptx
ATHEROSCLEROSIS pathophysiology .pptxImtiyaz60
 
PATHOLOGY OF HYPERTENSION .ppt
PATHOLOGY OF HYPERTENSION           .pptPATHOLOGY OF HYPERTENSION           .ppt
PATHOLOGY OF HYPERTENSION .pptImtiyaz60
 
Hypertension and its pathophysiology.pptx
Hypertension and its pathophysiology.pptxHypertension and its pathophysiology.pptx
Hypertension and its pathophysiology.pptxImtiyaz60
 
Appetite-stimulants-Digestants-and-carminatives.pptx
Appetite-stimulants-Digestants-and-carminatives.pptxAppetite-stimulants-Digestants-and-carminatives.pptx
Appetite-stimulants-Digestants-and-carminatives.pptxImtiyaz60
 
Anti Ulcer drugs pharmacology and classification
Anti Ulcer drugs pharmacology and classificationAnti Ulcer drugs pharmacology and classification
Anti Ulcer drugs pharmacology and classificationImtiyaz60
 
gingerasafoetida.pptx
gingerasafoetida.pptxgingerasafoetida.pptx
gingerasafoetida.pptxImtiyaz60
 
leprosy.pptx
leprosy.pptxleprosy.pptx
leprosy.pptxImtiyaz60
 
Tuberculosis.pptx
Tuberculosis.pptxTuberculosis.pptx
Tuberculosis.pptxImtiyaz60
 
strokepresentation-170712173032 (1).pptx
strokepresentation-170712173032 (1).pptxstrokepresentation-170712173032 (1).pptx
strokepresentation-170712173032 (1).pptxImtiyaz60
 
Thyroid gland.pptx
Thyroid gland.pptxThyroid gland.pptx
Thyroid gland.pptxImtiyaz60
 
inflammatory bowel diseas.pptx
inflammatory bowel diseas.pptxinflammatory bowel diseas.pptx
inflammatory bowel diseas.pptxImtiyaz60
 
tannins-170116185017.pptx
tannins-170116185017.pptxtannins-170116185017.pptx
tannins-170116185017.pptxImtiyaz60
 
Heart Failure.ppt
Heart Failure.pptHeart Failure.ppt
Heart Failure.pptImtiyaz60
 
tuberculosiscompletednew-170308134731.pptx
tuberculosiscompletednew-170308134731.pptxtuberculosiscompletednew-170308134731.pptx
tuberculosiscompletednew-170308134731.pptxImtiyaz60
 
2_2019_10_26!04_54_11_PM.ppt
2_2019_10_26!04_54_11_PM.ppt2_2019_10_26!04_54_11_PM.ppt
2_2019_10_26!04_54_11_PM.pptImtiyaz60
 
Electrophysiology_of_Heart.pptx
Electrophysiology_of_Heart.pptxElectrophysiology_of_Heart.pptx
Electrophysiology_of_Heart.pptxImtiyaz60
 
Hepatitis.pptx
Hepatitis.pptxHepatitis.pptx
Hepatitis.pptxImtiyaz60
 

More from Imtiyaz60 (20)

asthma .pptx
asthma                                             .pptxasthma                                             .pptx
asthma .pptx
 
Asthma and COPD PATHOPHYSIOLOGY .pptx
Asthma and COPD PATHOPHYSIOLOGY    .pptxAsthma and COPD PATHOPHYSIOLOGY    .pptx
Asthma and COPD PATHOPHYSIOLOGY .pptx
 
Angina and MI PATHOPHYSIOLOGY .pdf
Angina and MI PATHOPHYSIOLOGY       .pdfAngina and MI PATHOPHYSIOLOGY       .pdf
Angina and MI PATHOPHYSIOLOGY .pdf
 
ATHEROSCLEROSIS pathophysiology .pptx
ATHEROSCLEROSIS pathophysiology    .pptxATHEROSCLEROSIS pathophysiology    .pptx
ATHEROSCLEROSIS pathophysiology .pptx
 
PATHOLOGY OF HYPERTENSION .ppt
PATHOLOGY OF HYPERTENSION           .pptPATHOLOGY OF HYPERTENSION           .ppt
PATHOLOGY OF HYPERTENSION .ppt
 
Hypertension and its pathophysiology.pptx
Hypertension and its pathophysiology.pptxHypertension and its pathophysiology.pptx
Hypertension and its pathophysiology.pptx
 
Appetite-stimulants-Digestants-and-carminatives.pptx
Appetite-stimulants-Digestants-and-carminatives.pptxAppetite-stimulants-Digestants-and-carminatives.pptx
Appetite-stimulants-Digestants-and-carminatives.pptx
 
Anti Ulcer drugs pharmacology and classification
Anti Ulcer drugs pharmacology and classificationAnti Ulcer drugs pharmacology and classification
Anti Ulcer drugs pharmacology and classification
 
gingerasafoetida.pptx
gingerasafoetida.pptxgingerasafoetida.pptx
gingerasafoetida.pptx
 
leprosy.pptx
leprosy.pptxleprosy.pptx
leprosy.pptx
 
Tuberculosis.pptx
Tuberculosis.pptxTuberculosis.pptx
Tuberculosis.pptx
 
strokepresentation-170712173032 (1).pptx
strokepresentation-170712173032 (1).pptxstrokepresentation-170712173032 (1).pptx
strokepresentation-170712173032 (1).pptx
 
Thyroid gland.pptx
Thyroid gland.pptxThyroid gland.pptx
Thyroid gland.pptx
 
inflammatory bowel diseas.pptx
inflammatory bowel diseas.pptxinflammatory bowel diseas.pptx
inflammatory bowel diseas.pptx
 
tannins-170116185017.pptx
tannins-170116185017.pptxtannins-170116185017.pptx
tannins-170116185017.pptx
 
Heart Failure.ppt
Heart Failure.pptHeart Failure.ppt
Heart Failure.ppt
 
tuberculosiscompletednew-170308134731.pptx
tuberculosiscompletednew-170308134731.pptxtuberculosiscompletednew-170308134731.pptx
tuberculosiscompletednew-170308134731.pptx
 
2_2019_10_26!04_54_11_PM.ppt
2_2019_10_26!04_54_11_PM.ppt2_2019_10_26!04_54_11_PM.ppt
2_2019_10_26!04_54_11_PM.ppt
 
Electrophysiology_of_Heart.pptx
Electrophysiology_of_Heart.pptxElectrophysiology_of_Heart.pptx
Electrophysiology_of_Heart.pptx
 
Hepatitis.pptx
Hepatitis.pptxHepatitis.pptx
Hepatitis.pptx
 

Recently uploaded

Hybridoma Technology ( Production , Purification , and Application )
Hybridoma Technology  ( Production , Purification , and Application  ) Hybridoma Technology  ( Production , Purification , and Application  )
Hybridoma Technology ( Production , Purification , and Application ) Sakshi Ghasle
 
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Celine George
 
Class 11 Legal Studies Ch-1 Concept of State .pdf
Class 11 Legal Studies Ch-1 Concept of State .pdfClass 11 Legal Studies Ch-1 Concept of State .pdf
Class 11 Legal Studies Ch-1 Concept of State .pdfakmcokerachita
 
A Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformA Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformChameera Dedduwage
 
Crayon Activity Handout For the Crayon A
Crayon Activity Handout For the Crayon ACrayon Activity Handout For the Crayon A
Crayon Activity Handout For the Crayon AUnboundStockton
 
Solving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxSolving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxOH TEIK BIN
 
How to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxHow to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxmanuelaromero2013
 
Mastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory InspectionMastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory InspectionSafetyChain Software
 
Alper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentAlper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentInMediaRes1
 
Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)eniolaolutunde
 
Call Girls in Dwarka Mor Delhi Contact Us 9654467111
Call Girls in Dwarka Mor Delhi Contact Us 9654467111Call Girls in Dwarka Mor Delhi Contact Us 9654467111
Call Girls in Dwarka Mor Delhi Contact Us 9654467111Sapana Sha
 
Presiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsPresiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsanshu789521
 
Final demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptxFinal demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptxAvyJaneVismanos
 
Painted Grey Ware.pptx, PGW Culture of India
Painted Grey Ware.pptx, PGW Culture of IndiaPainted Grey Ware.pptx, PGW Culture of India
Painted Grey Ware.pptx, PGW Culture of IndiaVirag Sontakke
 
ENGLISH5 QUARTER4 MODULE1 WEEK1-3 How Visual and Multimedia Elements.pptx
ENGLISH5 QUARTER4 MODULE1 WEEK1-3 How Visual and Multimedia Elements.pptxENGLISH5 QUARTER4 MODULE1 WEEK1-3 How Visual and Multimedia Elements.pptx
ENGLISH5 QUARTER4 MODULE1 WEEK1-3 How Visual and Multimedia Elements.pptxAnaBeatriceAblay2
 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxNirmalaLoungPoorunde1
 
Pharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdfPharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdfMahmoud M. Sallam
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxiammrhaywood
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxpboyjonauth
 

Recently uploaded (20)

Hybridoma Technology ( Production , Purification , and Application )
Hybridoma Technology  ( Production , Purification , and Application  ) Hybridoma Technology  ( Production , Purification , and Application  )
Hybridoma Technology ( Production , Purification , and Application )
 
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
 
Class 11 Legal Studies Ch-1 Concept of State .pdf
Class 11 Legal Studies Ch-1 Concept of State .pdfClass 11 Legal Studies Ch-1 Concept of State .pdf
Class 11 Legal Studies Ch-1 Concept of State .pdf
 
A Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformA Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy Reform
 
Crayon Activity Handout For the Crayon A
Crayon Activity Handout For the Crayon ACrayon Activity Handout For the Crayon A
Crayon Activity Handout For the Crayon A
 
Solving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxSolving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptx
 
How to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxHow to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptx
 
Mastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory InspectionMastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory Inspection
 
Alper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentAlper Gobel In Media Res Media Component
Alper Gobel In Media Res Media Component
 
Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)
 
Call Girls in Dwarka Mor Delhi Contact Us 9654467111
Call Girls in Dwarka Mor Delhi Contact Us 9654467111Call Girls in Dwarka Mor Delhi Contact Us 9654467111
Call Girls in Dwarka Mor Delhi Contact Us 9654467111
 
Presiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsPresiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha elections
 
Staff of Color (SOC) Retention Efforts DDSD
Staff of Color (SOC) Retention Efforts DDSDStaff of Color (SOC) Retention Efforts DDSD
Staff of Color (SOC) Retention Efforts DDSD
 
Final demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptxFinal demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptx
 
Painted Grey Ware.pptx, PGW Culture of India
Painted Grey Ware.pptx, PGW Culture of IndiaPainted Grey Ware.pptx, PGW Culture of India
Painted Grey Ware.pptx, PGW Culture of India
 
ENGLISH5 QUARTER4 MODULE1 WEEK1-3 How Visual and Multimedia Elements.pptx
ENGLISH5 QUARTER4 MODULE1 WEEK1-3 How Visual and Multimedia Elements.pptxENGLISH5 QUARTER4 MODULE1 WEEK1-3 How Visual and Multimedia Elements.pptx
ENGLISH5 QUARTER4 MODULE1 WEEK1-3 How Visual and Multimedia Elements.pptx
 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptx
 
Pharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdfPharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdf
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptx
 

rheumatoidarthritispptbyann-160402080357.pptx

  • 2. DEFINITION  Rheumatoid arthritis (RA) is a chronic and usually progressive inflammatory disorder of unknown etiology characterized by polyarticular symmetrical joint involvement and systemic manifestations.
  • 3.  Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease that involves inflammation in the membrane lining of the joints and often affects internal organs.  Most patients exhibit a chronic fluctuating course of disease that can result in progressive joint destruction, deformity, and disability.  It occurs three times more often in women, and peaks at age 35 to 50 years.
  • 4. Rheumatoid arthritis is a chronic disease, characterized by periods of disease flares and remissions. The cause of rheumatoid arthritis is not known. In rheumatoid arthritis, multiple joints are usually, but not always, affected in a symmetrical pattern. Rheumatoid arthritis can affect people of all ages. Damage to joints can occur early and does not correlate with the severity of symptoms. The "rheumatoid factor" is an antibody that can be found in the blood of 80% of people with rheumatoid arthritis.
  • 5.
  • 6.  The cause of RA is not fully understood but appears to be multifactorial.  It is considered an autoimmune disease in which the body loses its ability to distinguish between synovial and foreign tissue. Other factors involved in RA are as follows:  1. Environmental influences, such as infections or trauma, smoking and tobacco are thought to trigger the development of RA. ETIOLOGY
  • 7. 2.Genetic markers, such as human leukocyte antigen DR4 (HLA-DR4), have been associated with triggering the inflammatory process in RA. Such markers, however, are not considered diagnostic because 30% of people with HLA-DR4 never develop RA. 3.Antigen-dependent activation of T lymphocytes leads to proliferation of the synovial lining, activation of proinflammatory cells from the bone marrow, cytokine and protease secretion, and autoantibody production.
  • 8. 4.Anticitrullinated proteins and peptides are high specific for RA. 5.Tumor necrosis factor & (TNF-&), IL-1, IL-6, IL-8, and growth factors propagate the inflammatory process, and agents found to alter these cytokines show promise in reducing pain and deformity. 6.Inflamed synovium is a hallmark of the pathophysiology of RA. Synovium proliferates abnormally, growing into the joint space and into the bone, forming a pannus. The pannus migrates to the articular cartilage and into the subchondral bone leading to destruction of cartilage, bone, tendons, and blood vessels.
  • 9. Genetic and environmental factors play a part. Gender. Women before the menopause are affected three times more often than men. After the menopause the frequency of onset is similar between the sexes, suggesting an etiological role for sex hormones. The use of the oral contraceptive pill has shown no affect on RA overall, as previously thought, but it may delay the onset of disease. Familial. The disease is familial with an increased incidence in first degree relatives and a high concordance amongst monozygotic twins (up to 15%) and dizygotic twins (3.5%). In occasional families it affects several generations.
  • 10. 12 Genetic factors are estimated to account for up to 60% of disease susceptibility. There is a strong association between susceptibility to RA and certain HLA haplotypes. HLA-DR4, which occurs in 50–75% of patients, correlates with a poor prognosis, as does HLA-DRB1. Individuals with HLA-DRB1 combined with a positive rheumatoid factor are13 times greater risk for developing bone erosions in early disease.
  • 12.
  • 13.  Chronic inflammation of the synovial tissue lining the joint capsule results in the proliferation of this tissue. The inflamed, proliferating synovium characteristic of rheumatoid arthritis is called pannus. This pannus invades the cartilage and eventually the bone surface, producing erosions of bone and cartilage and leading to destruction of the joint. The factors that initiate the inflammatory process are unknown.
  • 14. The immune system is a complex network of checks and balances designed to discriminate self from non- self (foreign) tissues. It helps rid the body of infectious agents, tumour cells, and products associated with the breakdown of cells. In rheumatoid arthritis, this system no longer can differentiate self from non-self tissues and attacks the synovial tissue and other connective tissues.
  • 15.
  • 16.
  • 17. Signs & Symptoms of RA • Fatigue. • Stiffness, especially in early morning and after sitting a long period of time. • Not relieved by pain • Low Grade Fever, Weakness. • Muscle pain and pain with prolonged sitting. • Symmetrical, affects joints on both sides of the body. • Rheumatoid nodules. • Deformity of your joints over time. • Raynauds phenomenon. • Pain
  • 18.
  • 19.
  • 20.  1. Rheumatoid factor (RF) is found in " 60% of patients with RA; however, as many as 5% of healthy individuals will have elevated titers of RF. If initially negative, the test can be repeated in 6 to 12 months. RF is not an accurate measure of disease progression. LABORATORY ASSESSMENT
  • 21. 2.Erythrocyte sedimentation rate (ESR) and C- reactive protein (CRP) : They are markers of inflammation and are usually elevated in patients with RA. They can also help indicate the activity of the disease, but they do not indicate disease severity. 3.Anticyclic citrullinated peptide antibodies (ACPA) : These are found in most patients with RA and are useful in predicting erosive disease.
  • 22. Radiographic examination: This can reveal the extent of bone erosion and cartilage loss. An MRI can detect proliferative pannus.
  • 23. Rheumatoid Arthritis  Symptom criteria – Morning stiffness – Arthritis of 3 or more joints – Arthritis of hand joints – Symmetric arthritis – Rheumatoid nodules – Serum rheumatoid factor – Radiographic changes  A person shall be said to have rheumatoid arthritis if he or she has satisfied 4 of 7 criteria, with criteria 1-4 present for at least 6 weeks
  • 24. Diagnosis and clinical evaluation: In 2010, EULAR (European League Against Rheumatism) established a score-based algorithm criteria aimed at diagnoses before joint damage occurs. Definitive RA is defined as a score # 6/10 based on four domains: 1.Joint involvement (e.g., number and location of involved joints) 2. Serology (e.g., RF, ACPA) 3. Acute phase reactants (e.g., CRP, ESR) 4. Duration of symptoms
  • 25.
  • 26. Treatment objectives  The goals in the management of RA are:  1. To prevent or control joint damage  2. To prevent loss of function  3. To decrease pain  4. To maintain the patient’s quality of life  5. To avoid or minimize adverse effects of treatment.  6. Preservation of muscle and joint function.  7. Return to a desirable and productive life.
  • 27. ALGORITHM OF TREATMENT OF RA Methotrexate Or other DMARD ± NSAID ± Prednisone within first 3 months Poor response Other DMARD mono Rx (MTX if not used above) Combo DMARD Rx Biologic DMARD Mono or combo with DMARD Poor response Try other combination, triple drug (DMARD + Biologic), add low dose of Prednisone for long term, consider second line DMARD.
  • 28. Non pharmacological Treatment  Diet  Exercise  Acupuncture  Herbal Medicines  Massage  Stress Reduction Techniques – prayer, meditation, hypnosis, yoga.
  • 29. Nutrition The most commonly observed vitamin and mineral deficiencies in patients with RA are: o folic acid o vitamin C o vitamin D o vitamin B6 o vitamin B12 o vitamin E o calcium o magnesium o zinc o selenium
  • 30. Exercise 4 times a week for 30 minutes Being overweight strains joints and leads to further inflammation. •Walking •Light jogging •Water aerobics •Cycling •Yoga •Tai chi •stretching
  • 31. Medications  There are four types of medications used to treat RA: – Non-steroidal anti-inflammatory drugs (NSAIDs) – Disease-modifying anti-rheumatic drugs(DMARDS). – Corticosteroids – Biologic Response Modifiers (“Bioligics”) (Arthritis Foundation, 2012; Gulanick & Myers 2011)
  • 32. Non-steroidal anti-inflammatory drugs (NSAIDs) Examples General Use Side Effects Nursing Considerations Aspirin, ibuprofen, naproxen, COX-2 inhibitors, propionic acid, phenylacetic acid •anti- inflammatory: Used in the management inflammatory conditions •Antipyretic: used to control fever •Analgesic: Control mild to moderate pain •Nausea •Vomiting •Diarrhea •Constipation •Dizziness •Drowsiness •Edema •Kidney failure •Liver failure •Prolonged bleeding •Ulcers •Use cautiously in patients with Rx of bleeding disorders •Encourage pt to avoid concurrent use of alcohol •NSAIDs may decrease response to diuretics or antihypertensive therapy
  • 33. Corticosteroids Examples General Use Side Effects Nursing Considerations Cortisone, hydrocortisone, prednisone, betamethasone,dex a-methasone •Used in the management inflammatory conditions •When NSAIDS may be contraindicate d •Promptly improve symptoms of RA •Increased appetite •Weight gain •Water/salt retention •Increased blood pressure •Thinning of skin •Depression •Mood swings •Muscle weakness •Osteoporosis •Delayed wound healing •Onset/worsenin g of diabetes •Take medications as directed (adrenal suppression) •Used with caution in diabetic patients •Encourage diet high in protein, calcium, potassium and low in sodium and carbohydrates •Discuss body image •Discuss risk for infection
  • 34. Disease-modifying anti-rheumatic drugs(DMARDS) Examples General Use Side Effects Nursing Considerations Methotrexate (the gold standard) , gold salts, cyclosporine, sulfasalazine, azathioprine •immunosuppressiv e activity •Reduce inflammation of rheumatoid arthritis •Slows down joint destruction •Preserves joint function •Dizziness, drowsiness, headache •Pulmonary fibrosis •Pneumonitis •Anorexia •Nausea •Hepatotoxicity •Stomatitis •Infertility •Alopecia •Skin ulceration •Aplastic anemia •Thrombocytopeni a •Leukopenia •Nephropathy •fever •photosensitivity •May take several weeks to months before they become effective •Discuss teratogenicity, should be taken off drug several months prior to conception •Discuss body image
  • 35. Biologic Response Modifiers (“Biologics”) Examples General Use Side Effects Nursing Considerations Etanercept, anakinra, abatacipt, adalimumab, Infliximab (Remicade) •Used in the management inflammatory conditions •When NSAIDS may be contraindicate d •Promptly improve symptoms of RA •Increased appetite •Weight gain •Water/salt retention •Increased blood pressure •Thinning of skin •Depression •Mood swings •Muscle weakness •Osteoporosis •Delayed wound healing •Onset/worsening of diabetes •T ake medications as directed (adrenal suppression) •Encourage diet high in protein, calcium, potassium and low in sodium and carbohydrates •Discuss body image •Discuss risk for infection
  • 36.
  • 38. • V COMMENT ON THERAPY